Skjalg Bruheim

1.2k total citations
15 papers, 925 citations indexed

About

Skjalg Bruheim is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Skjalg Bruheim has authored 15 papers receiving a total of 925 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 6 papers in Oncology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Skjalg Bruheim's work include Drug Transport and Resistance Mechanisms (3 papers), MicroRNA in disease regulation (2 papers) and Sarcoma Diagnosis and Treatment (2 papers). Skjalg Bruheim is often cited by papers focused on Drug Transport and Resistance Mechanisms (3 papers), MicroRNA in disease regulation (2 papers) and Sarcoma Diagnosis and Treatment (2 papers). Skjalg Bruheim collaborates with scholars based in Norway, United States and Japan. Skjalg Bruheim's co-authors include Øystein Fodstad, Jingfang Ju, Yaguang Xi, Bo Song, Marko Kornmann, A. Formentini, Elaine Gavin, Galina I. Botchkina, Yijun Wang and Kenji Kudo and has published in prestigious journals such as The EMBO Journal, PLoS ONE and Oncogene.

In The Last Decade

Skjalg Bruheim

15 papers receiving 908 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Skjalg Bruheim Norway	12	687	438	213	100	65	15	925
Paraskevi Alexandrou Greece	18	497 0.7×	280 0.6×	390 1.8×	82 0.8×	102 1.6×	43	922
Carole Chaboteaux Belgium	14	432 0.6×	323 0.7×	317 1.5×	82 0.8×	29 0.4×	22	771
Kathy A. Toy United States	17	666 1.0×	340 0.8×	358 1.7×	85 0.8×	17 0.3×	19	999
Zhiming Zhang China	17	580 0.8×	238 0.5×	158 0.7×	68 0.7×	34 0.5×	53	889
Shucai Yang China	13	509 0.7×	317 0.7×	230 1.1×	95 0.9×	39 0.6×	24	793
Rika Tsuchida Japan	12	572 0.8×	334 0.8×	310 1.5×	100 1.0×	19 0.3×	16	902
Wensheng Qiu China	17	518 0.8×	271 0.6×	215 1.0×	162 1.6×	24 0.4×	71	842
Marisa Mariani United States	15	476 0.7×	235 0.5×	249 1.2×	73 0.7×	32 0.5×	24	758
Yi Sang China	19	885 1.3×	433 1.0×	220 1.0×	108 1.1×	22 0.3×	44	1.1k
Lisa McPherson United States	17	735 1.1×	290 0.7×	306 1.4×	65 0.7×	24 0.4×	24	1.2k

Countries citing papers authored by Skjalg Bruheim

Since Specialization

Citations

This map shows the geographic impact of Skjalg Bruheim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Skjalg Bruheim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Skjalg Bruheim more than expected).

Fields of papers citing papers by Skjalg Bruheim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Skjalg Bruheim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Skjalg Bruheim. The network helps show where Skjalg Bruheim may publish in the future.

Co-authorship network of co-authors of Skjalg Bruheim

This figure shows the co-authorship network connecting the top 25 collaborators of Skjalg Bruheim. A scholar is included among the top collaborators of Skjalg Bruheim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Skjalg Bruheim. Skjalg Bruheim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

1.

Yan, Zhen, et al.. (2015). The novel HSP90 inhibitor NVP-AUY922 shows synergistic anti-leukemic activity with cytarabine in vivo. Experimental Cell Research. 340(2). 220–226. 11 indexed citations

2.

Bruheim, Skjalg, Marit Liland Sandvold, Gunhild M. Mælandsmo, & Øystein Fodstad. (2013). Antitumor activity of elacytarabine combined with bevacizumab, cetuximab and trastuzumab in human NSCLC xenografts.. PubMed. 33(9). 3615–21. 5 indexed citations

3.

Wang, Bin, Skjalg Bruheim, Jingfang Ju, et al.. (2011). Systematic Evaluation of Three microRNA Profiling Platforms: Microarray, Beads Array, and Quantitative Real-Time PCR Array. PLoS ONE. 6(2). e17167–e17167. 92 indexed citations

4.

Bruheim, Skjalg, Alexandr Kristian, Toshimitsu Uenaka, et al.. (2011). Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts. International Journal of Cancer. 129(3). 742–750. 28 indexed citations

5.

Bergman, Andries M., Jan Balzarini, Skjalg Bruheim, et al.. (2010). Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Investigational New Drugs. 29(3). 456–466. 78 indexed citations

6.

Olberg, Dag Erlend, Alan Cuthbertson, Magne Solbakken, et al.. (2010). Radiosynthesis and Biodistribution of a Prosthetic Group (¹⁸F-FENMA) Conjugated to Cyclic RGD Peptides. Bioconjugate Chemistry. 21(12). 2297–2304. 11 indexed citations

7.

Bruheim, Skjalg, Yaguang Xi, Jingfang Ju, & Øystein Fodstad. (2009). Gene Expression Profiles Classify Human Osteosarcoma Xenografts According to Sensitivity to Doxorubicin, Cisplatin, and Ifosfamide. Clinical Cancer Research. 15(23). 7161–7169. 33 indexed citations

8.

Bruheim, Skjalg, Gunhild M. Mælandsmo, Dag Erlend Olberg, et al.. (2009). Didanosine ester prodrugs: Synthesis, albumin binding properties and pharmacokinetic studies in rats. European Journal of Medicinal Chemistry. 44(10). 3874–3879. 5 indexed citations

9.

Song, Bo, Yijun Wang, Yaguang Xi, et al.. (2009). Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene. 28(46). 4065–4074. 325 indexed citations

10.

Nakajima, Go, Ana Patiño‐García, Skjalg Bruheim, et al.. (2008). CDH11 expression is associated with survival in patients with osteosarcoma.. PubMed. 5(1). 37–42. 41 indexed citations

11.

Bruheim, Skjalg, et al.. (2007). Antitumor activity of CP-4055 is enhanced in combination with bevacizumab, cetuximab, and trastuzumab in human NSCLC xenografts. Molecular Cancer Therapeutics. 6. 2 indexed citations

12.

Matsumoto, Tarô, Svante Bohman, Johan Dixelius, et al.. (2005). VEGF receptor‐2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. The EMBO Journal. 24(13). 2342–2353. 220 indexed citations

13.

Bruheim, Skjalg, Øyvind S. Bruland, Knut Breistøl, Gunhild M. Mælandsmo, & Øystein Fodstad. (2004). Human osteosarcoma xenografts and their sensitivity to chemotherapy. Pathology & Oncology Research. 10(3). 133–141. 36 indexed citations

14.

Bruheim, Skjalg, Kurt A. Krobert, Kjetil Wessel Andressen, & Finn Olav Levy. (2003). Unaltered Agonist Potency upon Inducible 5-HT 7(a) but not 5-HT 4(b) Receptor Expression Indicates Agonist-Independent Association of 5-HT 7(a) Receptor and G s. 9(2). 107–116. 15 indexed citations

15.

Bruheim, Skjalg, Kurt A. Krobert, Kjetil Wessel Andressen, & Finn Olav Levy. (2003). Unaltered Agonist Potency upon Inducible 5-HT 7(a) but not 5-HT 4(b) Receptor Expression Indicates Agonist-Independent Association of 5-HT 7(a) Receptor and G s. PubMed. 9(2). 107–116. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact